Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nibedita Bandyopadhyay"'
Autor:
Dingwei Ye, Katherine B. Bevans, Andrea J. Pereira de Santana Gomes, Sabine Brookman-May, Byung Ha Chung, Simon Chowdhury, Suneel Mundle, Álvaro Juárez, Ke Zhang, Kim N. Chi, Mustafa Ozguroglu, Anders Bjartell, Sharon Anne McCarthy, Julie S. Larsen, Neeraj Agarwal, Weili Sun, Robert Given, Nibedita Bandyopadhyay, Hirotsugu Uemura, Axel S. Merseburger
Publikováno v:
Journal of Clinical Oncology. 39:2294-2303
PURPOSE The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sen
Autor:
Laura E. Hogan, Teena Bhatla, David T. Teachey, Francisco José Bautista Sirvent, John Moppett, Pablo Velasco Puyó, Concetta Micalizzi, Claudia R?Ssig, Neerav Shukla, Gil Gilad, Franco Locatelli, Andre Baruchel, C. Michel Zwaan, Elizabeth A. Raetz, Nibedita Bandyopadhyay, Lorena Lopez Solano, Robyn Monet Dennis, Robin L. Carson, Ajay Vora
Publikováno v:
Journal of Clinical Oncology. 40:10001-10001
10001 Background: Approximately 15-20% of pediatric pts with ALL or LL will be refractory to/relapse after frontline treatment; relapsed disease is associated with poor outcomes. In a phase 2 study, 2 of 7 (28.6%) pts with T-cell ALL in first relapse
Autor:
Emerson A. Lim, Michael Thomas Schweizer, Kim N. Chi, Rahul Raj Aggarwal, Neeraj Agarwal, James L. Gulley, Edward F. Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron Richard Hansen
Publikováno v:
Journal of Clinical Oncology. 40:279-279
279 Background: PSMA expression is increased in response to anti-androgen therapies and is a promising therapeutic target for the treatment of prostate cancer (PCa). JNJ-081 is a bispecific antibody with one arm binding PSMA on cancer cells and the o
Autor:
Anders Bjartell, Weili Sun, Suneel Mundle, Spyros Triantos, Katherine B. Bevans, Ke Zhang, Mustafa Ozguroglu, Byung Ha Chung, Simon Chowdhury, Kim N. Chi, Sharon Anne McCarthy, Andrea J. Pereira de Santana Gomes, Robert Given, Axel S. Merseburger, Julie S. Larsen, Nibedita Bandyopadhyay, Hirotsugu Uemura, Neeraj Agarwal, Álvaro Juárez Soto, Dingwei Ye
Publikováno v:
Journal of Clinical Oncology. 39:11-11
11 Background: TITAN evaluated APA or PBO added to ADT in pts with mCSPC. Pts with high- and low-volume disease, prior docetaxel, prior treatment for localized disease, and prior ADT (≤ 6 mos) were eligible. At the first interim analysis, with 22.7